Past year
All results
- All results
- Verbatim
Feb 12, 2024 · While in the early development stages, our new formulation has demonstrated active drug release in <30 seconds, 90% bioavailability, and a safe and well ...
Apr 3, 2024 · Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update. VANCOUVER, B.C., April 03, 2024. Alpha Cognition Inc.
Dec 7, 2023 · The NDA has been granted a Prescription Drug User Fee Act (PDUFA) goal date of July 27th, 2024. “The FDA's acceptance of our NDA for ALPHA-1062 brings us ...
Dec 4, 2023 · (“Alpha Cognition” or the “Company”) announces that it has amended the terms of its previously announced private placement offering of up to US$6.5 million of ...
Feb 12, 2024 · ALPHA-1062's NDA was accepted by the FDA on December 06, 2023, with a PDUFA date set for July 27, 2024. The potential approval would mark a milestone, offering ...
Nov 28, 2023 · The Company expects FDA approval in the second half of 2024. We believe that ALPHA-1062 will offer a meaningful differentiated therapy for patients with ...
7 days ago · Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update - read this article along with other careers information, tips and ...
Dec 7, 2023 · Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease.
Mar 1, 2024 · Alpha Cognition filed new composition of matter patent for world-wide review in February. If approved, the patent extends ALPHA-1062 patent life from 2042 to ...
People also search for
Jun 3, 2023 · Approval for ALPHA-1062 will be based on demonstrating bioequivalence to galantamine. The pivotal program delivered positive results at the end of 2022, and the ...
Missing: press | Show results with:press